Secondary cytoreductive surgery for recurrent ovarian cancer improves overall survival - BJMO
This #ASCO20 was notable for two major trials exploring secondary cytoreductive surgery in recurrent #ovariancancer - DESKTOP III and SOC -1 #ASCO20 # - Thread from Shannon Westin @ShannonWestin - Rattibha
A trial looking at surgery for ovarian cancer that has come back (DESKTOP 3, ENGOT ov20) | Cancer Research UK
IJGC on X: "#podcast: The DESKTOP III Trial with Philipp Harter This week, @pedroramirezMD is joined by Prof. Philipp Harter to discuss The DESKTOP III Trial. ♫https://t.co/CZQXdMT97W @_kem @IGCSociety @ESGO_society @OncoAlert @agz_eriksson #
Clinical Conundrums: Choosing the Best Management Approaches in Patients With Ovarian Cancer Thomas J. Herzog, MD Director, Division of Gynecologic Oncology. - ppt download
JGO :: Journal of Gynecologic Oncology
Diapositiva 1
Stream episode The DESKTOP III Trial with Philipp Harter by BMJ talk medicine podcast | Listen online for free on SoundCloud
Randomized Trial of Cytoreductive Surgery for Relapsed Ovarian Cancer | NEJM
Shannon Westin, MD, MPH, FASCO on X: "Patient selection clearly matters - DESKTOP III used the AGO criteria, SOC-1 used iMODEL score - both have been validated to predict ability to achieve
Secondary cytoreduction followed by chemotherapy versus chemotherapy alone in platinum-sensitive relapsed ovarian cancer (SOC-1): a multicentre, open-label, randomised, phase 3 trial - The Lancet Oncology
REVEL Trial Design for metastatic NSCLC | CYRAMZA® (ramucirumab)
Randomized Trial of Cytoreductive Surgery for Relapsed Ovarian Cancer | NEJM
Randomized Trial of Cytoreductive Surgery for Relapsed Ovarian Cancer | NEJM
573P Role of CA125 in patients included in the DESKTOP III/ENGOT-ov20 trial
PPT - AGO-OVAR DESKTOP III (Protocol AGO - OVAR OP.4) PowerPoint Presentation - ID:3272978
GEMSTONE Educational Module Last Update: April 9, ppt download
2020 ASCO Annual Meeting - Conference Program - Clin Onc 2020 - 22991 | CCO
Biostatistics Software Downloadable or Online
GRIPHON Trial for Pulmonary Arterial Hypertension (PAH)
Frontiers | Prediction Models for Complete Resection in Secondary Cytoreductive Surgery of Patients With Recurrent Ovarian Cancer
This #ASCO20 was notable for two major trials exploring secondary cytoreductive surgery in recurrent #ovariancancer - DESKTOP III and SOC -1 #ASCO20 # - Thread from Shannon Westin @ShannonWestin - Rattibha
